Soleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year Low – What’s Next?

Soleno Therapeutics, Inc. (NASDAQ:SLNO)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $31.71 and last traded at $31.72, with a volume of 969231 shares. The stock had previously closed at $33.22.

Key Stories Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Neutral Sentiment: Wall Street Zen cut SLNO to a “Hold” (ratings action may temper near‑term momentum but is not a sell recommendation). Soleno Therapeutics (NASDAQ:SLNO) Cut to “Hold” at Wall Street Zen
• Negative Sentiment: A securities class action complaint was filed alleging Soleno misled investors about DCCR (VYKAT XR) safety and launch issues; the lawsuit cites the March–November 2025 class period and seeks damages, raising potential legal exposure and reputational risk. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Multiple plaintiff firms (Faruqi & Faruqi, Levi & Korsinsky, Kessler Topaz, Glancy Prongay, Bronstein, Rosen, Robbins Geller, Schall, DJS, etc.) are actively soliciting investors and reminding of the May 5, 2026 deadline to seek lead‑plaintiff status — amplifying publicity, potential settlement pressure, and near‑term volatility. SLNO CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on SLNO shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Zacks Research lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Wall Street Zen cut shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday. Robert W. Baird set a $107.00 price objective on shares of Soleno Therapeutics in a report on Tuesday, January 13th. Finally, Wolfe Research set a $60.00 price objective on shares of Soleno Therapeutics in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Soleno Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $104.54.

Soleno Therapeutics Stock Down 4.5%

The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The stock has a market cap of $1.64 billion, a PE ratio of 137.92 and a beta of -3.16. The business has a 50 day moving average price of $39.39 and a 200 day moving average price of $49.46.

Soleno Therapeutics (NASDAQ:SLNO) last posted its earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Equities research analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Soleno Therapeutics

Several institutional investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC lifted its stake in shares of Soleno Therapeutics by 12.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock valued at $134,270,000 after purchasing an additional 322,223 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Soleno Therapeutics during the fourth quarter valued at $38,000. Seven Fleet Capital Management LP acquired a new stake in Soleno Therapeutics during the fourth quarter valued at $6,023,000. Virtu Financial LLC purchased a new position in Soleno Therapeutics in the fourth quarter valued at $1,059,000. Finally, Empowered Funds LLC purchased a new position in Soleno Therapeutics in the fourth quarter valued at $69,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.